FDA extends indication of metastatic breast cancer treatment to include male patients

[News]

The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

More... (https://www.news-medical.net/news/20190405/FDA-extends-indication-of-metastatic-breast-cancer-treatment-to-include-male-patients.aspx)